Retinal Deep Phenotyping.TM

Sponsor
Optina Diagnostics Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05903664
Collaborator
(none)
500
1
12
41.6

Study Details

Study Description

Brief Summary

This study aims to collect a baseline dataset of MHRC retinal scans that will be used for the pre-training of deep learning models from the hyperspectral retinal image phenotypic features that may form the basis for multiple future classification applications.

As an exploratory study, there are no endpoints per se, however, the following sub-objective will be evaluated for determining the success of this study:

  • Collection and characterization of MHRC retinal images from at least 250 participants that score at least 80 on the real-time Quality Index (included in the MHRC software).

  • Development of at least one (1) DL model of the retina. Models may be used for the development of novel classifier tests and potential use in a clinical setting.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is an exploratory, observational, cross-sectional, multi-site study designed to collect a baseline dataset of MHRC retinal image scans for use in Deep Learning models. Subjects will be recruited from eye clinics where patients will undergo mydriasis (pupil dilation) as part of their clinical visit. Eligible participants will be provided information about the study and delegated site personnel will assist with the Informed Consent process. If a participant provides their Informed Consent, they will be enrolled in the study and undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Retinal Deep PhenotypingTM by A Novel Mydriatic Hyperspectral Retinal Camera (MHRC) And Analysis by Deep Learning
    Anticipated Study Start Date :
    Jul 31, 2023
    Anticipated Primary Completion Date :
    Jul 31, 2024
    Anticipated Study Completion Date :
    Jul 31, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Single group assignment

    The participant will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.

    Outcome Measures

    Primary Outcome Measures

    1. At least one (1) Deep Learning (DL) model that characterizes the retina. [12 months]

    2. Review of any safety events (AE, SAE, UADEs) that occur throughout the study. [12 months]

      As an exploratory study, there are no acceptance criteria for these study outcomes, rather the study results will be summarized in a Final Clinical Study report that will document the study outcomes and any learnings/models that may be applied to new development project using the MHRC H5 images

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Adults 18 years and older who will undergo mydriasis (pupil dilation) as part of their eye clinic visit.
    Exclusion Criteria:
    • Contraindications for mydriatic fundus imaging.

    • Pupil dilation contraindicated (due to a pathology, or presence of 3 quadrants with Van Herick grading of 0 or 1 without iridotomy).

    • Inadequate pupil dilatation (< 6mm diameter) preventing uniform illumination of the retina with the MHRC.

    • Refractive error outside the range of -15 D to +15 D.

    • Deficient visual fixation (inability to fixate for at least 2 s)

    • Inability of obtaining at least 3 images of satisfactory quality with the MHRC per the Optina Diagnostics quality index software and /or per the eye specialists' evaluation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wagner Macular & Retinal Center Norfolk Virginia United States 23502

    Sponsors and Collaborators

    • Optina Diagnostics Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Optina Diagnostics Inc.
    ClinicalTrials.gov Identifier:
    NCT05903664
    Other Study ID Numbers:
    • 22-002A
    First Posted:
    Jun 15, 2023
    Last Update Posted:
    Jun 15, 2023
    Last Verified:
    Jun 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jun 15, 2023